InMed Pharmaceuticals (IN) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period InMed Pharmaceuticals (TSE:IN) Trading Down 1.6% - Time to Sell?December 17, 2024 | americanbankingnews.comInMed Pharmaceuticals Reports Improved Quarterly EarningsNovember 19, 2024 | markets.businessinsider.comInMed Announces Share Consolidation to Satisfy Nasdaq Listing RulesNovember 9, 2024 | finance.yahoo.comInMed Pharmaceuticals granted Nasdaq compliance extensionNovember 7, 2024 | uk.investing.comInMed Pharmaceuticals Showcases INM-901 at Biotech WebinarOctober 26, 2024 | markets.businessinsider.comInMed seeks appeal over Nasdaq delisting noticeSeptember 23, 2024 | investing.comCBDNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market GrowthAugust 30, 2024 | msn.com3 Penny Stocks to Watch Now, 8/22/24August 22, 2024 | msn.comInMed Pharmaceuticals (NASDAQ:INM) Stock, Insider Trading ActivityAugust 21, 2024 | benzinga.comInMed Pharmaceuticals (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”August 9, 2024 | theglobeandmail.comINM Stock Earnings: InMed Pharmaceuticals Reported Results for Q3 2024May 14, 2024 | msn.comInMed Pharmaceuticals (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD StudiesApril 6, 2024 | theglobeandmail.comInMed Pharmaceuticals: InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business UpdateFebruary 13, 2024 | finanznachrichten.deInMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business UpdateFebruary 13, 2024 | finance.yahoo.comInMed Pharmaceuticals (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside ChatJanuary 22, 2024 | theglobeandmail.comInMed Pharmaceuticals Provides Business Update and Milestones for 2024January 16, 2024 | finance.yahoo.comInMed’s (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer’s with a Rare Cannabinoid AnalogDecember 12, 2023 | finance.yahoo.comInMed Pharmaceuticals (NASDAQ: INM) Advancing INM-089 to Target Treatment of Age-Related Macular DegenerationNovember 30, 2023 | theglobeandmail.comInMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular DegenerationNovember 29, 2023 | finance.yahoo.comInMed Pharmaceuticals GAAP EPS of -$0.76, revenue of $901.8MNovember 14, 2023 | msn.comInMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept StudiesOctober 24, 2023 | finance.yahoo.comCannabis Industry Report Highlights Positive Sentiment and Growth Potential at Benzinga ConferenceOctober 13, 2023 | benzinga.comDelveInsight Business Research, LLP: Epidermolysis Bullosa Market to Surge at a CAGR of ~8% During the Study Period (2019-2032), Predicts DelveInsightAugust 11, 2023 | finanznachrichten.deInMed Provides Update on BayMedica Rare Cannabinoid BusinessJuly 20, 2023 | finance.yahoo.comGame-Changer In Epidermolysis Bullosa Treatment? Cannabis Compound Holds PromiseJuly 7, 2023 | msn.comBiosynthesis of Cannabinoids Market Growth By 2030April 25, 2023 | marketwatch.comBlepharitis-Pipeline Market Description and Business Overview By 2030April 20, 2023 | marketwatch.comInMed Pharmaceuticals: Pushing Pharma Forward With Rare CannabinoidsMarch 27, 2023 | benzinga.comDespite Global Economic Pressures, InMed Pharma's Accomplishments In 2022 Could Be A Catalyst For Further Growth In 2023March 17, 2023 | benzinga.comInMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin ConditionsMarch 13, 2023 | finance.yahoo.comInMed Pharmaceuticals Q2 FY23 Revenue Grows 77% YoY, What About Net Loss?February 21, 2023 | benzinga.comEpidermolysis Bullosa Market is Booming in Near Future 2023-2028 with Top Countries DataFebruary 20, 2023 | marketwatch.comInMed Pharmaceuticals Inc.: InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business UpdateFebruary 20, 2023 | finanznachrichten.deInMed Pharmaceuticals GAAP EPS of -$0.91, revenue of $0.47MFebruary 17, 2023 | msn.comInMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business UpdateFebruary 17, 2023 | yahoo.comInMed Submits Form 12b-25February 10, 2023 | finance.yahoo.comGlobal Blepharitis-Pipeline Market Size Growth Rate Analysis 2023 by Market Overview, Segments, Regions, Market Share and Forecast to 2028January 24, 2023 | marketwatch.comThinking about buying stock in Geron Corp, InMed Pharmaceuticals, Kingsoft Cloud, Vivos Therapeutics, or Baozun?January 4, 2023 | marketwatch.comSpasticity Treatment Market Research Highlighting Global Opportunities 2023 | Growth Trends and Share Forecast to 2029December 14, 2022 | marketwatch.comInMed Announces Appointment of Interim Chief Financial Officer and Change of AuditorDecember 12, 2022 | nz.finance.yahoo.comBiotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory UpdateNovember 23, 2022 | msn.comInMed (INM) Gets Grant to Begin Neurodegenerative Diseases ProgramNovember 17, 2022 | finance.yahoo.comWhy Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day SessionNovember 16, 2022 | msn.comThinking about buying stock in Fast Radius, Camber Energy, InMed Pharmaceuticals, Taiwan Semiconductor, or Exela Technologies?November 16, 2022 | benzinga.comInMed stock rockets after research grant awarded for cannabinoid analogs to treat Alzheimer's, Parkinson'sNovember 16, 2022 | msn.comInMed Pharmaceuticals Inc.: InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business UpdateNovember 12, 2022 | finanznachrichten.deInMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business UpdateNovember 12, 2022 | benzinga.comInMed Pharmaceuticals Shares Rise 30% on Higher-Than-Normal VolumeSeptember 30, 2022 | marketwatch.comInMed Pharma Gains 9%September 9, 2022 | nasdaq.comInMed Pharma to Consolidate SharesAugust 25, 2022 | marketwatch.com Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IN and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Coin for November 2024 (Ad)Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… IN Media Mentions By Week IN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IN News Sentiment▼0.000.60▲Average Medical News Sentiment IN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IN Articles This Week▼10▲IN Articles Average Week Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OSS News Today HPQ News Today SCY News Today CRDL News Today HLS News Today MDP News Today DB News Today LABS News Today CWEB News Today CTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:IN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
